Log In Sign up
The largest database of trusted experimental protocols

Lacidipine

Manufactured by Merck Group
Visit Supplier

Lacidipine is a pharmaceutical compound used in the production of laboratory equipment. It functions as an active ingredient in the manufacturing process of various laboratory instruments and tools. No further details on its intended use or application are provided.

Automatically generated - may contain errors

Lab products found in correlation

Carbadox, by Merck Group (1 mentions) Acyclovir, by Merck Group (1 mentions) Isradipine, by Merck Group (1 mentions) Nifedipine, by Merck Group (1 mentions) Alloxazine, by Merck Group (1 mentions) Felodipine, by Merck Group (1 mentions) Nandrolone, by Merck Group (1 mentions) Isoproterenol, by Merck Group (1 mentions) Gw5074, by Merck Group (1 mentions) Gsk 429286, by Bio-Techne (1 mentions) Hy l022, by MedChemExpress (1 mentions)

2 protocols using lacidipine

1

Dose-Dependent Differentiation Modulation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were treated for 48 h beginning at day 2 of differentiation with DMSO (vehicle control, ATCC), aceclidine (Sigma-Aldrich), acyclovir (Sigma-Aldrich), alloxazine (Sigma-Aldrich), carbadox (Sigma-Aldrich), felodipine (Sigma-Aldrich), GW5074 (Sigma-Aldrich), isoproterenol (Sigma-Aldrich), isradipine (Sigma-Aldrich), lacidipine (Sigma-Aldrich), nafadotride (Tocris Bioscience), nandrolone (Sigma-Aldrich), nifedipine (Sigma-Aldrich), nilvadipine (Sigma-Aldrich), alloxazine (Sigma-Aldrich) diluted in cell-type specific differentiation media at doses listed in figures.
Shu C., Kaxon-Rupp A.N., Collado J.R., Damoiseaux R, & Crosbie R.H. (2019). Development of a high-throughput screen to identify small molecule enhancers of sarcospan for the treatment of Duchenne muscular dystrophy. Skeletal Muscle, 9, 32.
+ Open protocol
+ Expand
2

Screening FDA-Approved Compounds for Cardiovascular Disease

Check if the same lab product or an alternative is used in the 5 most similar protocols
We constructed a subset library of approximately 150 compounds with research area annotation of cardiovascular disease from the FDA-approved drug library (HY-L022, MedChemExpress). Compounds were dissolved in dimethylsulfoxide (DMSO), transferred to 96-well plates, and stored at −80 °C. A calcium channel blocker (Lacidipine), and selective MLCK inhibitor (ML7) were purchased from Sigma. Caspase inhibitor (Z-VAD1-FMK) and selective ROCK1/2 inhibitor (GSK429286) were purchased from TOCRIS.
Nawrot D.A., Ozer L.Y, & Al Haj Zen A. (2022). A Novel High Content Angiogenesis Assay Reveals That Lacidipine, L-Type Calcium Channel Blocker, Induces In Vitro Vascular Lumen Expansion. International Journal of Molecular Sciences, 23(9), 4891.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!